Ilera Healthcare To Host Free Screening Of Award-Winning Veteran MMJ Documentary ‘Unprescribed’

November 15th Screening In Plymouth Meeting, PA

PENNSYLVANIA: Pennsylvania medical marijuana company and dispensary, Ilera Healthcare, will host a free screening of Unprescribed, followed by a panel discussion, on Friday, November 15th at 6:30 pm at Greater Plymouth Community Center in Plymouth Meeting.  The documentary film highlights medical marijuana (MMJ) as an alternative to the cocktail of drugs prescribed by military doctors for veterans struggling with PTSD, anxiety and other service-related health issues.

For many of our returning veterans, the battle continues out of uniform as they attempt to recover from war-related trauma through a multitude of prescription medicines.  In his first feature-length motion picture, producer, director, and Air Force veteran Steve Ellmore presents us with stories from fellow veterans, spouses, and family members on coping with war-related injuries and the loss of loved ones due to suicide. After returning from combat these veterans are prescribed what many refer to as the ‘combat cocktail’ or ‘zombie dope,’ leading many to believe that suicide is a possible solution to their pain.  The film takes a closer look at medical marijuana, which could provide a safer alternative for many returning soldiers. Unprescribed has recently won the Grand Jury Prize for Best Documentary Film at the Los Angeles Motion Picture Festival, Best Feature Documentary at the 2019 Cannabis Culture Film Festival, and was theBe the Change Winner at the Colorado International Activism Film Festival.  Unprescribed is also an official selection at the 2019 London Cannabis Film Festival, San Francisco Veterans Film Festival, and Honor Film Festival.   

At the conclusion of the screening, Ellmore will join Ilera’s Chief Scientific Officer Dr. Oludare Odumosu ,  clinical psychiatrist Dr. Lynn Bornfriend, Ron Milward of Balanced Veterans, Bill Ferguson of Veteran Cannabis Coalition, and veteran advocate and social media influencer Derek Carter on a panel to further explore MMJ as it pertains to easing the physical and mental pain of those returning from the armed forces. 

Also featured on the panel will be Christian Ryan, an MMJ advocate and US Army combat veteran, who served in Iraq. Besides advocating for veterans to have access to MMJ through his founding of the Veterans Medical Marijuana Advisory Council (V.M.M.A.C.), Christian, who is employed at Ilera, inspired the development of the company’s new  FREEDOM medical cannabis formulation.  

Greater Plymouth Community Center is located at 2910 Jolly Road in Plymouth Meeting, Pennsylvania.  To reserve free tickets to the Unprescribed screening and panel Q&A please visit.  

TerrAscend Completes Acquisition Of Ilera Healthcare

Expands licensed cannabis footprint to four U.S. states, in addition to global reach into Canada and Europe

CANADA: TerrAscend, the first and only global cannabis company licensed for sales in Canada, the US, and the EU, announced it has closed on its previously announced acquisition of Pennsylvania-based Ilera Healthcare, one of five permitted vertically-integrated cannabis cultivator, processor, and dispensary operators in the state. With the completion of this transaction, TerrAscend’s licensed cannabis footprint expands to four U.S. states, in addition to its global reach into Canada and Europe.

“As one of only 5 holders of Super Licenses in a limited license state with approximately 13 million people, Ilera is an ideal partner for TerrAscend to enter the Pennsylvania market with,” said Matthew Johnson, President of TerrAscend Corp., and TerrAscend USA, Inc. “We welcome Greg and the rest of the Ilera team to the TerrAscend family, and we look forward to partnering together as we continue to build the leading North American Operator (NAO) in the cannabis space.”

Greg Rochlin, CEO of Ilera, said, “By combining forces with TerrAscend, we see clear opportunities ahead for our stakeholders, employees and patients. We look forward to accelerating the growth of Ilera’s brands and formulations by leveraging TerrAscend’s platform in other markets. I can’t wait to introduce our wholesale customers and patients to the California-born Valhalla and State Flower brands, as well as Haven Street, a leading premium Canadian brand.”

Osagie Imasogie, Chairman of the Board for Ilera Healthcare added, “We know that Ilera’s original mission to deliver consistent premium cannabis medicines to patients throughout Pennsylvania will be carried on by TerrAscend, who shares our culture, and above all, our commitment to the highest standards of quality and patient service.”

Ilera currently operates a retail dispensary in Plymouth Meeting, PA, with plans to open two additional dispensary sites in the Philadelphia area within the next six months. The operations include a 67,000 square foot site for cultivation and processing in Waterfall, PA with planned expansion to over 120,000 square feet in 2020. In addition to selling its products in its own dispensary, Ilera distributes its dried flower, concentrates, tinctures, and topicals to over 60 dispensaries throughout Pennsylvania. Ilera’s current revenue run-rate is over US$43 million1, up from total sales in 2018 of less than US$8 million1. For more information about Ilera Healthcare.

The Pennsylvania medical marijuana program has more than 180,000 registered patients and 20,000 registered caregivers as of August 2019, and covers 23 qualifying medical conditions including anxiety disorders, cancer, and opioid use disorder3. Those seeking more information about Pennsylvania’s medical marijuana program can visit www.medicalmarijuana.pa.gov.

Transaction Details: The transaction closed at previously disclosed terms.

TerrAscend reiterates its current 2019 guidance of revenue in excess of C$141 million, which includes contribution from the Ilera transaction and pending disclosed transactions, as previously announced on August 22, 2019.

Tikun Olam and Ilera Healthcare Announce Pennsylvania Partnership

PENNSYLVANIA and NEW YORK:  Tikun Olam, the world leader in cannabis science, and Ilera Healthcare, Pennsylvania’s premier medical marijuana cultivator, processor and dispenser, have finalized a deal to bring Tikun’s world-renowned medical marijuana strains to medical cannabis patients in the Keystone State later this year.

This partnership combines Tikun Olam’s history of peer-reviewed scientific research and unprecedented clinical data collection with Ilera’s expertise in formulating and delivering high-quality pharmaceutical-grade medical cannabis products to Pennsylvanians. Products developed from Tikun Olam’s proprietary strains, including its world-renowned Avidekel high-CBD strain, will be available in vape oils, tinctures and topical formulations.

Tikun Olam has created numerous cannabis strains designed to deliver symptomatic relief for specific conditions in line with the 17 medical conditions approved for medical cannabis use in Pennsylvania, including autism, cancer, PTSD, epilepsy, Crohn’s Disease/Colitis, chronic pain and neuropathy, to name a few.
“Tikun Olam has spent years developing our strains through scientific methods,” says Tikun CEO Bernie Sucher. “Finding the ideal partner that shares our focus on quality control and consistency from seed to sale was a top priority for our Pennsylvania launch, and Ilera Healthcare was our top choice.”
Greg Rochlin, CEO of Ilera Healthcare, sees this as a natural partnership. “Ilera is dedicated to producing consistent, high-quality medications with effects that are supported by data, and so is Tikun Olam.”